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and follow-up assessments were calculated up to 18 months for neurocognition and 60 months for HRQoL.
RESULTS 28/30 patients were analyzed. The three preselected HRQoL scales (role, social and cognitive
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worse during follow-up compared to post-treatment scores and remained impaired during 18 months
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lexical verbal fluency improved compared to post-treatment scores, and remained within the normal
range thereafter. Other tests of verbal fluency were stable over time, with z-scores within the normal
range. CONCLUSIONS This long-term follow-up study showed that the NOA-07 treatment regimen
was not associated with a deterioration in HRQoL in the post-treatment period. Verbal working mem-
ory deteriorated, while other neurocognitive domains did not seem to be impacted negatively by the
treatment.
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Abstract
Background Combined radiochemotherapy followed by maintenance chemotherapy with cisplatin, lomustine and vincristine 
within the NOA-07 study resulted in considerable short-term toxicity in adult medulloblastoma patients. Here we investigated 
the long-term impact of this treatment, focusing on neurocognitive functioning and health-related quality of life (HRQoL).
Methods Neurocognitive functioning and HRQoL scores over time were determined, and differences between the post-
treatment and follow-up assessments were calculated up to 18 months for neurocognition and 60 months for HRQoL.
Results 28/30 patients were analyzed. The three preselected HRQoL scales (role, social and cognitive functioning) showed 
improved scores, to a clinically relevant extent (≥ 10 points), compared to post-treatment levels up to 30 months, but 
decreased afterwards. Z-scores for verbal working memory were worse during follow-up compared to post-treatment scores 
and remained impaired during 18 months follow-up (i.e. z-score below − 1 standard deviation). Attention was impaired 
post-treatment, and remained impaired to a clinically relevant extent during follow-up. Coordination/processing speed and 
lexical verbal fluency improved compared to post-treatment scores, and remained within the normal range thereafter. Other 
tests of verbal fluency were stable over time, with z-scores within the normal range.
Conclusions This long-term follow-up study showed that the NOA-07 treatment regimen was not associated with a deteriora-
tion in HRQoL in the post-treatment period. Verbal working memory deteriorated, while other neurocognitive domains did 
not seem to be impacted negatively by the treatment.
Keywords Brain tumor · Medulloblastoma · Cognition · Quality of life · Patient-reported outcome · Toxicity
Introduction
Medulloblastoma is a rare entity in adults, with an incidence 
of 0.6 cases per million persons per year [1]. Within the 
adult population, the disease typically affects young adults, 
at a median age between 20 and 40 years [2–4]. Current 
standard of care consists of surgery, radiotherapy and/or 
chemotherapy, but newer therapies including immunother-
apy and targeted therapy are being explored, particularly 
in the pediatric population [5]. Despite multimodal anti-
tumor treatment, tumor recurrence is inevitable in part of the 
patients. Recently reported 5- and 10-year overall survival 
rates ranged between 74 and 82% [1, 4, 6] and between 65 
and 67%, respectively [1, 6], and depend on clinical charac-
teristics of patients and the histological and genetic profile 
of the tumor. [3, 4, 6–8].
Medulloblastoma patients may suffer from a variety of 
symptoms, depending on the tumor location [9, 10] and its 
subsequent treatment. Anti-tumor treatment may alleviate 
the symptoms caused by the tumor, but may also result in 
early and late toxicity [2, 3, 11]. In the short-term, patients 
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with medulloblastoma may experience problems with 
coordination and gait. Increased intracranial pressure may 
cause symptoms such as headache, nausea and vomiting. 
When metastasized to the cerebrospinal fluid, back pain, 
muscle weakness, and loss of bladder and bowel function 
are frequent problems. Common acute toxicities in adult 
patients with medulloblastoma treated with radiochemo-
therapy are bone marrow suppression, polyneuropathy and 
ototoxicity [2].
As medulloblastoma patients have a relatively long 
survival, the impact of treatment on the patients’ long-
term functioning and well-being should also be considered 
during treatment decision-making. Most of the long-term 
adverse effects are not self-limiting. One of the most rel-
evant long-term complications of radiotherapy in brain 
tumor patients is neurocognitive dysfunction [12], which 
may subsequently interfere with a patients’ functioning 
in daily life, particularly role and social functioning. 
Although it has been shown that a large proportion of adult 
medulloblastoma patients have impaired neurocognitive 
functioning shortly after diagnosis, particularly in the 
domains learning, memory, and executive function [13], 
data on the short- and long-term impact of treatment on 
outcomes such as neurocognition and HRQoL are limited. 
One study reported impaired executive function, weak-
ness, ataxia, depression and anxiety about nine years after 
radiotherapy [14]. A review on core deficits and quality of 
survival in childhood medulloblastoma survivors showed 
long-term neurological and sensory (e.g. hearing loss) 
problems, endocrine dysfunction, neurocognitive impair-
ments (particularly in the domains information processing 
speed, attention and working memory) and psychosocial 
problems, particularly with role and social functioning 
[15]. In knowledge of these possible short- and long-term 
side effects, information on both the quantity and quality 
of survival should be available when informing patients on 
the benefits and risks of a treatment strategy. The NOA-07 
study investigated a combined radiochemotherapy of the 
neuroaxis with a boost to the posterior fossa in combi-
nation with vincristine, followed by maintenance chemo-
therapy with cisplatin, lomustine and vincristine with the 
main endpoint of toxicity-related treatment terminations 
after four cycles of adjuvant chemotherapy, and the acute 
toxicity profile in adult patients. Previously, the short-term 
impact of treatment in this study was investigated, showing 
considerable toxicity during active treatment, but improve-
ments in HRQoL and neurocognitive functioning [2]. Here 
we describe the long-term disease burden, up to five years 
after diagnosis, of adult medulloblastoma patients treated 
in the NOA-07 study in terms of neurocognitive function-




Adult (age ≥ 21 years) medulloblastoma patients with a 
Chang stage T1–4 and M0 or M1 were included. Further 
details on the study population are available elsewhere [2]. 
The study was approved by the ethical review boards of all 
participating centers, and patients provided written informed 
consent before participation.
Study design and treatment
NOA-07 was a prospective study in which all patients 
received photon craniospinal irradiation (35.2 Gy in 22 
fractions of 1.6 Gy, with a posterior fossa boost of 55 Gy in 
fractions of 1.8 Gy) in combination with vincristine (1.5 mg/
m2 per week), followed by a maximum of eight six-week 
cycles of cisplatin (70 mg/m2; day 1), lomustine (75 mg/m2; 
day 1) and vincristine (1.5 mg/m2; days 1, 8 and 15). Fur-
ther details on the treatment schedule have been published 
previously [2].
Outcomes
Primary endpoints of NOA-07 study were toxicity-related 
treatment terminations after four cycles of adjuvant chemo-
therapy, and acute toxicity profile. Event-free, progression-
free and overall survival were secondary endpoints, as were 
neurocognitive functioning and HRQoL.
Neurocognitive functioning
A neurocognitive test battery was used to assess several rel-
evant domains. Since the representations of working memory, 
word fluency and attention involve cerebellar functions to a 
substantial level [16–19], these domains were chosen. The 
digit span forward and backward test from the German ver-
sion of the Wechsler Adult Intelligence Scale-Revised [20] was 
used to assess attention span and verbal working memory. Trail 
Making Test Parts A and B [21] were used to measure coordi-
nation/processing speed and divided attention. Lexical verbal 
fluency was assessed with the Controlled Oral Word Asso-
ciation (COWA) test [22], while semantic verbal fluency was 
measured with the Regensburger Wortfluessigkeitstest [23]. 
To reduce practice effects, tests were chosen with minimal 
effects by repeated measurements [24]. Raw test scores were 
converted into z-scores, adjusting for age, sex and education, 
using population-based, normative data (means and standard 
deviations), provided by the respective test author in the test 
manual. A difference in z-score of -1 standard deviation (SD) 
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was chosen as cut-off to indicate impaired performance of 
patients as compared to the norm population, as well as to 
indicate a clinically relevant change over time [2, 19, 25]. Neu-
rocognitive functioning was evaluated between resection and 
the start of combined radiochemotherapy and after adjuvant 
chemotherapy, and subsequently every three months for up to 
24 months, after which neurocognition was assessed every six 
months up to 60 months.
HRQoL
The EORTC core Quality of Life Questionnaire (QLQ-C30, 
version 3.0) was used in combination with the brain cancer 
module (QLQ-BN20). Both instruments have shown robust 
psychometric properties [26–28]. Following the EORTC 
scoring manual, raw item scores were aggregated and trans-
formed into linear scales ranging from 0 to 100 [29]. For 
functional scales, a higher score represents better function-
ing, while for the symptom scales/items a higher score repre-
sents a higher level of symptoms. A difference ≥ 10 points on 
any scale/item was deemed clinically relevant [30]. HRQoL 
was evaluated between resection and the start of combined 
radiochemotherapy, after the conclusion of adjuvant chemo-
therapy, and subsequently every 3 months thereafter for up 
to 24 months, after which HRQoL was assessed every six 
months up to 60 months. Based on clinical experience, long-
term social outcome was considered most relevant to adult 
medulloblastoma patients, who are typically younger adults 
with an active family and social life. Therefore, three scales 
were selected for primary analysis: role functioning (RF), 
cognitive functioning (CF) and social functioning (SF). All 
other scales/items were analyzed on an exploratory basis.
Statistical analysis
Descriptive statistics
Sociodemographic and clinical characteristics of the patients 
included in this study were reported by means of descrip-
tive statistics, as were (changes in) neurocognitive function-
ing and HRQoL scores. Patients with data available at the 
moment of disease progression were included in the analy-
ses. Compliance with neurocognitive and HRQoL assess-
ments as determined for each included follow-up moment 
was calculated by dividing the number of completed tests 
or HRQoL forms at a specific time point by the number of 
expected test scores or forms at that moment.
Longitudinal course of neurocognitive functioning 
and HRQoL
Graphs were constructed to assess neurocognitive function-
ing and HRQoL scores over time, and a visual description 
provided accordingly. Wilcoxon signed rank test was used to 
calculate whether the differences between the post-treatment 
and follow-up neurocognitive and HRQoL scores were sta-
tistically significant, but these analyses should be considered 
exploratory due to the limited number of patients. In addi-
tion, the percentage of patients with impaired neurocognitive 
functioning was calculated at each time point, separately for 
each domain.
A sub-analysis was performed in those patients with fol-
low-up HRQoL data beyond 36 months, to gain more insight 
into their HRQoL trajectory. To do so, an average score dur-
ing treatment was compared with the average score during 
long-term follow-up, which was defined as the average in 
a specific HRQoL scale score between 36 and 60 months 
follow-up.
All statistical analyses were done with SPSS version 25.0 
(Armonk, NY: IBM Corp), and a p-value < 0.05 was consid-
ered statistically significant.
Results
A total of 28 out of 30 eligible patients completed at least 
one valid HRQoL questionnaire or underwent neurocog-
nitive testing and were included in this analysis. Included 
patients were on average 37 (SD 10) years of age, the major-
ity (61%) was male, and the median KPS at inclusion was 
90. Most tumors were in the classic and desmoplastic/
nodular entities. All patients had undergone resection and 
received combined radiochemotherapy. Eighty-nine per-
cent of patients received at least one cycle of chemother-
apy (median 6; range 0–8). During follow-up, five patients 
had disease progression after a median of 1.8 years (range 
1.1–4.5), and the 3- and 5-year event-free survival rate was 
66.6% each. The progression-free and overall survival rates 
were 66.6% for PFS after 3- and 5-years, and 70% for OS 
after 3- and 5-years, respectively (Table 1).
Compliance with HRQoL and neurocognitive 
assessments
At the pre-treatment assessment, compliance with HRQoL 
assessments was 86%, which decreased over time to 33% 
after 5 years of follow-up (Fig. 1). The average compliance 
rate for HRQoL over time was 65%. For neurocognitive 
testing these percentages were slightly lower: 50% compli-
ance at the pre-treatment assessment, which dropped to 11% 
after 5 years of follow-up. Because compliance was < 30% 
from 18 months onwards for neurocognitive testing, these 
analyses were conducted up to 18 months only. Reasons 
for drop-out were the decision of the investigator to ter-
minate treatment (8%), toxicity (29%), withdrawal of con-
sent (29%), non-compliance (8%) and progressive disease 
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(25%). See Supplemental Table 1 for the clinical character-
istics of patients included in the 18-month neurocognitive 
assessments.
Health‑related quality of life
As previously reported [2], treatment resulted in an improve-
ment of role, cognitive and social functioning on the group 
level [2]. Compared to post-treatment scores, none of the fol-
low-up scores was significantly different for any of the pre-
selected scales. Although the numbers of patients decreased 
over time, resulting in a limited number of patients avail-
able for analysis (< 10 patients beyond 36 months follow-
up), the results show that role functioning did improve to a 
clinically relevant extent compared to post-treatment levels 
up to 30 months, but decreased afterwards. Similar trends 
were observed for cognitive and social functioning (Fig. 2), 
and also for the exploratory HRQoL scales/items (data not 
shown).
To gain more insight into the HRQoL trajectory of 
those patients with available long-term follow-up data 
(i.e. ≥ 36 months), we compared scores during treatment 
with those during long-term follow-up. For the 12 eligible 
patients, we found that the average score for social function-
ing was higher at long-term follow-up than during treatment 
(77 vs. 50, p = 0.006). For role and cognitive functioning, 
treatment and long-term follow-up scores were not different; 
respectively 69 vs. 81 (p = 0.126) for role functioning, and 
73 vs. 69 (p = 0.397) for cognitive functioning.
Table 1  Baseline sociodemographic and clinical characteristics of 
medulloblastoma patients in the NOA-07 study who completed at 
least one valid health-related quality of life form or underwent neuro-
cognitive testing at least once
SD standard deviation, KPS Karnofsky Performance Status
Baseline characteristics
(n = 28)
Age in years at diagnosis




KPS, median (range) 90 (50–100)




Molecular entity, no. (%)




 Group 4 5 (17.9%)
 Not available 1 (3.5%)
Radiochemotherapy completed 28 (100%)
Adjuvant chemotherapy received 25 (89%)
Chemotherapy cycles, median (range) 6 (0–8)
Disease progression, no. (%) 5 (18%)
Progression-free survival in years, median 
(range); (n = 5)
1.8 (1.1–4.5)
5-year overall survival rate (%) 70%
Fig. 1  Compliance with health-related quality of life assessments and neurocognitive testing
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Fig. 2  Mean health-related quality of life scores and its 95% confidence interval over time, from the postoperative assessment (before radio-
chemotherapy) up to five years of follow-up for the preselected scales a role functioning, b cognitive functioning and c social functioning
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Neurocognitive functioning
The median number of tests on which patients had impaired 
neurocognitive functioning was 3 before treatment, 3.5 after 
treatment and ranged between 1.5 and 3.5 during follow-up 
(Table 2).
Attention span and verbal working memory
The digit span forward test showed that the mean z-scores 
during follow-up were lower than the post-treatment 
z-scores: 0.4 during the post-treatment assessment versus 
− 1.79 at 3 months follow-up (p = 0.012) and − 1 at the 
18-month assessment (p = 0.027), indicating the bottom of 
normal performance. The amelioration between the 3- and 
18-month assessment was significant (p = 0.043), but not 
clinically relevant (Fig. 3a). The findings on group level are 
supported by the findings on individual patient levels, show-
ing that the percentage of impaired patients increased from 
19% post-treatment to between 50 and 90% during follow-up 
(Table 2).
Whereas the digit span backward test was in the nor-
mal range before and directly after the treatment, working 
memory was impaired (z-score > − 1) at all time points 
except after 9 months follow-up (z-score = − 0.8) (Fig. 3b). 
Differences were statistically significant and clinically 
C 
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Fig. 2  (continued)
Table 2  Percentage of patients with impaired neurocognitive functioning (z-score < − 1 SD) over time, separately for each domain
Pre-treatment Post-treatment 3 m FU 6 m FU 9 m FU 12 m FU 15 m FU 18 m FU
Trail Making Test-A 8/14 (57%) 10/16 (63%) 5/10 (50%) 4/10 (40%) 1/7 (14%) 3/6 (50%) 2/7 (29%) 1/6 (17%)
Trail Making Test-B 9/14 (64%) 11/16 (69%) 7/10 (70%) 8/10 (80%) 4/7 (57%) 2/6 (33%) 4/7 (57%) 3/6 (50%)
Digit span forward 1/14 (7%) 3/16 (19%) 9/10 (90%) 6/10 (60%) 6/7 (86%) 3/6 (50%) 6/8 (75%) 5/7 (71%)
Digit span backward 2/14 (14%) 5/16 (31%) 8/10 (80%) 6/10 (60%) 3/7 (43%) 4/6 (67%) 4/8 (50%) 5/7 (71%)
Lexical fluency 10/13 (77%) 10/14 (71%) 2/10 (20%) 3/10 (30%) 2/7 (29%) 1/6 (17%) 3/8 (38%) 3/7 (43%)
Animal naming 5/14 (36%) 8/16 (50%) 1/10 (10%) 4/10 (40%) 1/7 (14%) 1/6 (17%) 4/8 (50%) 3/7 (43%)
Food naming 6/13 (46%) 7/14 (50%) 2/10 (20%) 4/10 (40%) 2/7 (29%) 1/6 (17%) 3/8 (38%) 2/7 (29%)
Median (range) tests impaired 3 (1–6) 3.5 (0–7) 3.5 (1–5) 3.5 (1–6) 3 (0–5) 1.5 (0–5) 3.5 (0–6) 3 (0–6)
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relevant between the post-treatment z-score and the 3- 
and 6-month follow-up assessment z-scores (p = 0.027 and 
p = 0.028, respectively). On the individual patient level, 
the results also indicated that the majority of patients 
had impaired working memory over time, except after 
9 months of follow-up (43%; Table 2).
Divided attention and coordination/processing speed
Performance in divided attention (TMT B) did not change 
during follow-up when compared to the post-treatment 
assessment (Fig. 3c). Although the z-score was close to nor-
mal at the 18 months follow-up assessment (z-score = − 1.1), 
attention remained impaired during follow-up. On 
Fig. 3  Mean Z-scores and 95% 
confidence interval for the 
different neurocognitive tests 
over time; a Attention span 
(digit span forward), b working 
memory (digit span backward), 
c divided attention (Trail Mak-
ing Test B), d coordination/
processing speed (Trail Making 
Test A), e lexical word fluency, 
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the individual level it was also shown that the major-
ity of patients, except for the 12-month assessment (33% 
impaired), had impaired divided attention.
Coordination/processing speed (TMT A) was impaired 
during the post-treatment assessment (z-score = − 1.4), 
but improved into the normal range at 3 months follow-up 
(z-score = − 0.9, p = 0.028) and remained stable afterwards 
(Fig. 3d). Indeed, during the post-treatment assessment, 63% 
of patients had impaired coordination/processing speed, 
which decreased to 17–50% of patients during follow-up.
Verbal fluency
Lexical word fluency was impaired to a clinically relevant 
extent before and directly after treatment, but improved dur-
ing follow-up, with scores ranging between − 0.1 and − 0.8 
(Fig. 3e), which are in the normal range. Compared to the 
post-treatment assessment, patients had significantly and 
clinically relevant better z-scores at 9-, 12- and 15-months 
follow-up (all p < 0.05). This was also reflected on the indi-
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Fig. 3  (continued)
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lexical word fluency during the post-treatment assessment, 
and between 17 and 43% during follow-up (Table 2).
For the animal naming test, the post-treatment score 
was in the normal range, which was continued during fol-
low-up, with no significant differences between the post-
treatment and follow-up z-scores (Fig. 3f). Although in 
the normal range, results on the individual level showed 
that half of patients had impaired animal naming during 
the post-treatment assessment, and this percentage ranged 
between 10 and 50% during follow-up (Table 2).
Although the post-treatment score for food naming was 
impaired on the group level, follow-up scores were all in the 
normal range, ranging between − 0.5 (3 months) and − 1 
(18 months) (Fig. 3g), although this improvement was nei-
ther statistically significant nor clinically relevant. Similarly, 
on the individual level it was shown that 50% of patients had 
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Fig. 3  (continued)
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and this percentage decreased (ranging between 17 and 40%) 
during follow-up (Table 2).
Discussion
Treatment of adult medulloblastoma patients in the NOA-07 
study with combined radiochemotherapy of the neuroaxis 
followed by maintenance chemotherapy with cisplatin, 
lomustine and vincristine has been shown, in the short-
term, to result in considerable toxicity during active treat-
ment, however paralleled by improvements in HRQoL and 
neurocognitive functioning [2]. Here, we present mid- to 
long-term analyses on HRQoL and neurocognitive function-
ing, with the goal to better understand the impact of radio-
chemotherapy on the patients’ longer term functioning and 
well-being. In general, this analysis showed that the NOA-07 
treatment regimen on group level did not result in a (fur-
ther) deterioration of HRQoL or neurocognitive function-
ing, except for verbal working memory, in the post-treatment 
period. It should be noted though, that a substantial part of 
the study population did experience impaired neurocognitive 
functioning during follow-up as shown by the analysis on the 
individual patient level (Table 2).
The impact of treatment on neurocognition and HRQoL 
in adult medulloblastoma patients is understudied. A recent 
study reported impaired neurocognitive functioning (learning 
and memory, and executive function) shortly after diagnosis 
[13], while another study reported that adult medulloblastoma 
patients had problems with executive dysfunction, weakness, 
ataxia, depression or anxiety about nine years after radiother-
apy [14]. These long-term sequelae may subsequently have 
a negative impact on HRQoL. In NOA-07 study, HRQoL 
scores remained lower than in healthy controls [2], as did 
neurocognitive scores. In pediatric patients, severe and per-
sistent deficits in neurocognitive functioning were observed 
after median 10 years posttreatment with radiotherapy and/
or chemotherapy, with significant impairments in aspects of 
daily living [31, 32], but not HRQoL [32]. Another study 
reported no long-term impact on HRQoL 6 years after proton 
therapy, although scores were below those of healthy controls 
[33]. Besides neurocognitive impairments, survivors of child-
hood medulloblastoma also often experience neurological 
deficits such as hearing loss and endocrine dysfunction [15], 
which have shown to negatively impact HRQoL in patients 
with pituitary adenoma [34] or vestibular schwannoma [35].
As medulloblastoma in adults typically affects younger 
patients, long-term social outcome of treatment is of main 
interest. This study showed that social functioning as meas-
ured with the EORTC QLQ-C30, reflecting the impact of 
disease and treatment on the patient’s family and social life, 
improved over time, although scores remained well below 
that of the general population [36]. Other important survi-
vorship issues [37], such as career opportunities and limiting 
of life plans/goals are currently investigated only in child-
hood medulloblastoma [38]. Certainly, a broader approach 
would provide more insight into the long-term disease bur-
den in this disease. Adding items from the EORTC item 
Library [39] to the core HRQoL questionnaire and brain 
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Fig. 3  (continued)
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In the 18-month post-treatment period of NOA-07, we 
observed clinically relevant dysfunction in the domains divided 
attention and working memory, which remained stable over 
time. Indeed, over time, the majority of patients experienced 
impairments in these domains. Previous studies have shown 
that isolated cerebellar lesions can cause impairments in work-
ing memory [19]. There is also mounting evidence that the 
cerebellum not only participates in working memory, but also 
in other higher-order cognitive tasks such as executive process-
ing, verbal fluency and planning as well as linguistic and affec-
tive performance [16–18]. An anatomical substrate for these 
functions is a cerebellar feedback loop through the thalamus 
and prefrontal and inferior parietal lobule of the parietal cortex 
as reported for primates. Therefore, a major cause of neuro-
cognitive dysfunction in these tumors seems tumor location. 
Nevertheless, in children it has been shown that craniospinal 
radiotherapy with posterior fossa boost has an additional severe 
negative impact on neurocognition [40–43]. This effect may be 
less pronounced in young adults or too early to be detected. In 
patients with low-grade glioma, the presence of a tumor had the 
most detrimental impact on the patient’s neurocognitive func-
tioning. Treatment with radiotherapy in fractions > 2 Gy did 
result in neurocognitive dysfunction after a median of six years 
after diagnosis [44], and after a median of 12 years after diag-
nosis also fractions ≤ 2 Gy were associated with neurocogni-
tive dysfunction [12]. Radiotherapy dose reduction has impact 
on reducing neurocognitive toxicity. Long-term radiotherapy-
induced structural sequelae as leukoencephalopathy and radia-
tion-induced vasculopathy relate to neurocognitive deficits [45, 
46]. Neurocognitive impairment after cranial irradiation is more 
severe in children, but also prevalent in adults [14]. The boost 
radiotherapy volume can be reduced to the tumor bed only in 
children without losing efficacy in comparison to posterior 
fossa irradiation, if a dose of 50 Gy is sustained [47, 48]. Also, 
a reduction of the craniospinal dose to 23.4 Gy in combination 
with chemotherapy has been investigated in pediatric trials and 
showed non-inferior efficacy [49]. However, both approaches 
were not investigated in adults in a prospective manner so far. 
As there is mounting evidence from pediatric trials that radio-
therapy dose is associated with neurocognitive dysfunction, 
efforts to reduce radiotherapy dose and boost volume should 
be undertaken in well-selected adult medulloblastoma patients, 
without compromising tumor control.
The association between neurocognitive function-
ing and HRQoL has already been shown in patients with 
brain tumors, but not in adults with medulloblastoma, with 
worse HRQoL scores in patients with impaired neurocogni-
tive functioning [50]. Although the limited sample size in 
NOA-07 refrained us from analyzing whether a change in 
neurocognitive functioning was associated with a change in 
HRQoL, we would expect that impaired neurocognition has 
a negative impact on the patients’ HRQoL, particularly on 
the longer term.
Due to the small sample size and decreasing compli-
ance over time, a common problem with neurocognitive 
and HRQoL assessments during follow-up in prospective 
brain tumor studies [51–54], long-term analysis of neuro-
cognitive functioning beyond 18 months was not possible. 
In general, longer term results for both neurocognition and 
HRQoL should be interpreted with caution, as patients with 
better prognosis or good response to treatment are typi-
cally overrepresented during follow-up [55–57]. The find-
ing that HRQoL improved up to 30 months after which a 
deterioration was observed, is likely caused by drop-out of 
patients over time, and is not necessarily a reflection of the 
development of long-term toxicity. This is supported by our 
sub-analysis in those patients with follow-up ≥ 36 months, 
showing that social, role and cognitive functioning improved 
or remained stable in the post-treatment period. Another 
limitation is that this study reflects a trial population, with 
stringent inclusion criteria, hampering generalizability 
of the results to the entire adult medulloblastoma patient 
population. Moreover, both neurocognition and HRQoL are 
impacted by other factors than treatment alone, including 
age, tumor course, comorbidity and supportive treatment 
[58, 59]. According to this, in glioma patients, progression 
was found to be the main cause of deterioration in HRQoL, 
and not treatment [60]. Due to the limited number of patients 
with progression and available neurocognitive or HRQoL 
data at the moment of progression, the impact of progres-
sion of the patients’ functioning and well-being could not be 
evaluated in this study. Similarly, subgroup analyses were 
not considered meaningful because of the small sample size, 
while certain aspects may be associated with neurocogni-
tive functioning and possibly HRQoL. For example, differ-
ent molecular subtypes and germline polymorphisms [61] 
have shown to be associated with neurocognitive functioning 
in childhood medulloblastoma patients, and patients who 
did or did not complete the entire treatment regimen may 
also differ in their level of functioning. Lastly, changes in 
neurocognition and HRQoL on the individual patient level 
were not considered meaningful due to the limited number 
of patients available for analysis, even though these analyses 
may provide more detailed information on the impact of 
treatment. Indeed, presenting data on group level only may 
result in an underestimation of the actual problems.
In conclusion, posttreatment data of the NOA-07 study 
showed that combined radiochemotherapy followed by 
maintenance chemotherapy in general does not result in 
a deterioration of the functioning and well-being of adult 
medulloblastoma patients on the medium long term. Nev-
ertheless, a larger adequately powered trial with a higher 
number of patients is needed to confirm these findings, 
and to prove the benefits of reduced radiotherapy dose 
and boost volume in adult medulloblastoma patients. Cur-
rently, a large international trial, EORTC 1634-BTG, is 
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being developed at the EORTC to investigate a personal-
ized intensity-modulated therapy in post-pubertal patients 
with newly-diagnosed medulloblastoma, in which neuro-
cognitive functioning and HRQoL are included as major 
secondary outcomes.
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